ClinicalTrials.gg
Active, not recruitingNCT03673501INTRIGUEUpdated Oct 16, 2026Results posted

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

A Phase 3 interventional study of Ripretinib and Sunitinib in Gastrointestinal Stromal Tumors, sponsored by Deciphera Pharmaceuticals, LLC. Active, not recruiting at 121 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Deciphera Pharmaceuticals, LLC (part of Ono Pharmaceutical Co. Ltd) · Phase 3, Interventional, and Treatment

Updated Oct 16, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
453
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd — 2 open to participants now, 5 under way, 2 of them phase 3. Gastrointestinal Stromal Tumors · Ono Pharmaceutical Co. Ltd.

Started
2019
the only one that year
Phase 3
3 of 10
none open now
Registered
3rd of 10
by date

Among the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd, this one is the only one that started in 2019, is one of 3 in phase 3, and was the 3rd registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

2 of the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd, or all of them as a file.
02

Study summary

This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to ripretinib 150 mg once daily (continuous dosing for 6 week cycles) or sunitinib 50 mg once daily (6 week cycles, 4 weeks on, 2 weeks off).

03

Conditions studied

  • Gastrointestinal Stromal Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥ 18 years of age at the time of .
  2. Histologic diagnosis of GIST and must be able to provide an sample, otherwise, a fresh biopsy is required.
  3. Molecular pathology report must be available. If molecular pathology report is not available or insufficient, an archival tumor tissue sample or fresh biopsy is required for mutation status confirmation by the central laboratory prior to randomization.
  4. Patients must have progressed on imatinib or have documented intolerance to imatinib.
  5. (ECOG) Performance Score (PS) of ≤ 2 at screening.
  6. Female patients of must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test at screening and negative pregnancy test at Cycle 1 Day 1 prior to the first dose of study drug.
  7. Patients of must agree to follow the requirements outlined in the study protocol.
  8. Patients must have at least 1 according to Modified () Version 1.1 (non nodal lesions must be ≥ 1.0 cm in the long axis or ≥ double the slice thickness in the long axis) within 21 days prior to the first dose of study drug.
  9. Adequate organ function and bone marrow reserve as indicated by the central laboratory assessments performed at screening.
  10. Resolution of all toxicities from prior therapy to ≤ Grade 1 (or patient baseline) within 1 week prior to the first dose of study drug (excluding alopecia and ≤ Grade 3 clinically asymptomatic lipase, amylase, and creatine phosphokinase laboratory abnormalities).
  11. The patient is capable of understanding and complying with the protocol and the patient has signed the informed consent document. Signed informed consent form (ICF) must be obtained before any study-specific procedures are performed and the patient must agree to not participate in any other interventional clinical trial while on treatment in this clinical trial. Participation in a noninterventional study (including observational studies) is permitted.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with any other in addition to imatinib for advanced GIST. Imatinib-containing combination therapy in the first-line setting is not allowed.
  2. Patients with a prior or concurrent whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of this clinical trial are not eligible.
  3. Patient has known active central nervous system .
  4. class II-IV heart disease, myocardial infarction within 6 months of cycle 1 day 1, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, cardiac arrhythmia requiring therapy, uncontrolled hypertension or congestive heart failure.
  5. (LVEF) \< 50% at screening.
  6. Arterial thrombotic or embolic events such as cerebrovascular accident (including ischemic attacks) or hemoptysis within 6 months before the first dose of study drug.
  7. Venous thrombotic events (e.g. deep vein thrombosis) or pulmonary arterial events (e.g. pulmonary embolism) within 1 month before the first dose of study drug. Patients on stable anticoagulation therapy for at least one month are eligible.
  8. 12-lead demonstrating corrected (QTc) by Fridericia's formula > 450 ms in males or > 470 ms in females at screening or history of long QTc syndrome
  9. Use of known substrates or inhibitors of breast cancer resistance protein (BCRP) transporters within 14 days or 5 x the half-life (whichever is longer) prior to the first dose of study drug.
  10. Major surgeries (e.g. abdominal laparotomy) within 4 weeks of the first dose of study drug. All major surgical wounds must be healed and free of infection or dehiscence before the first dose of study drug.
  11. Any other clinically significant comorbidities.
  12. Known or infection only if the patient is taking medications that are excluded per protocol, active , or active hepatitis C infection.
  13. If female, the patient is pregnant or lactating.
  14. Known allergy or to any component of the study drug.
  15. Gastrointestinal abnormalities including but not limited to:

    • inability to take oral medication
    • malabsorption syndromes
    • requirement for intravenous (IV) alimentation
  16. Any active bleeding excluding hemorrhoidal or gum bleeding.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
453 participants (actual)

Study arms

  • Experimental
    Ripretinib

    Ripretinib (150 mg) once a day continuous dosing for 6-week (42 days) cycles

    Drug: Ripretinib

  • Active comparator
    Sunitinib

    Sunitinib (50 mg) once a day in 6-week (42 days) cycles with 4 weeks continuous dosing followed by 2 week break.

    Drug: Sunitinib

Interventions

  • Oral KIT/PDGFRA kinase inhibitor

    Also known as: DCC-2618

  • Oral receptor tyrosine kinase (RTK) inhibitor

    Also known as: Sutent

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) in the KIT Exon 11 Intent to Treat (ITT) Population

    PFS is defined as the interval between the date of randomization and the earliest documented evidence of disease progression based on the independent radiologic review using modified RECIST Version 1.1-(mRECIST 1.1) GIST specific, or death due to any cause. Per mRECIST 1.1, progression was defined using mRECIST 1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: From date of randomization to earliest documented evidence of disease progression, or death due to any cause (up to 2.1 years)

  2. Progression Free Survival (PFS) in the All Patient (AP) Intent to Treat (ITT) Population

    PFS is defined as the interval between the date of randomization and the earliest documented evidence of disease progression based on the independent radiologic review using modified RECIST Version 1.1-(mRECIST 1.1) Gastrointestinal stromal tumor (GIST) specific, or death due to any cause. Per mRECIST 1.1, progression was defined using mRECIST 1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: From date of randomization to earliest documented evidence of disease progression, or death due to any cause (up to 2.1 years)

Secondary outcomes

  1. Objective Response Rate (ORR) in the KIT Exon 11 Intent to Treat (ITT) Population Population

    ORR was defined as the proportion of patients with confirmed complete response (CR) + confirmed partial response (PR) based on independent radiologic review using modified RECIST (mRECIST) criteria as best overall response. Per mRECIST 1.1 criteria, complete response is defined as disappearance of all target lesions; partial response is defined as \>=30% decrease in the sum of the longest diameter of target lesions.

    Time frame: From confirmed CR or PR to disease progression (up to 1.74 years)

  2. Objective Response Rate (ORR) in the All Patient (AP) Intent to Treat (ITT) Population

    ORR was defined as the proportion of patients with confirmed complete response (CR) + confirmed partial response (PR) based on independent radiologic review using modified RECIST (mRECIST) criteria as best overall response. Per mRECIST 1.1 criteria, complete response is defined as disappearance of all target lesions; partial response is defined as \>=30% decrease in the sum of the longest diameter of target lesions.

    Time frame: From confirmed CR or PR to disease progression (up to 1.74 years)

  3. Overall Survival (OS) in the KIT Exon 11 Intent to Treat (ITT) Population

    OS was defined as the time from the date of randomization until death due to any cause.

    Time frame: From date of randomization until death due to any cause (up to 3.33 years)

  4. Overall Survival (OS) in the All Patient (AP) Intent to Treat (ITT) Population

    OS was defined as the time from the date of randomization until death due to any cause.

    Time frame: From date of randomization until death due to any cause (up to 3.33 years)

07

Results

Posted Jan 2, 2024

Participant flow

Participant flow — Overall Study
MilestoneRipretinibSunitinib
Started226227
Completed190203
Not completed3624
Withdrew: Participants ongoing.3624

Outcome measures

PrimaryProgression Free Survival (PFS) in the KIT Exon 11 Intent to Treat (ITT) Population

PFS is defined as the interval between the date of randomization and the earliest documented evidence of disease progression based on the independent radiologic review using modified RECIST Version 1.1-(mRECIST 1.1) GIST specific, or death due to any cause. Per mRECIST 1.1, progression was defined using mRECIST 1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
From date of randomization to earliest documented evidence of disease progression, or death due to any cause (up to 2.1 years)
Reported as:
Median · months
Progression Free Survival (PFS) in the KIT Exon 11 Intent to Treat (ITT) Population
monthsRipretinibSunitinib
Progression Free Survival (PFS) in the KIT Exon 11 Intent to Treat (ITT) Population8.3 (6.8 to 13.3)7.0 (5.6 to 10.9)
Statistical analysis
  • Ripretinib vs Sunitinib · Log Rank · p = 0.3598 · Hazard ratio (hr): 0.88 · 95% CI 0.66 to 1.16Strata: by intolerance to imatinib treatment
PrimaryProgression Free Survival (PFS) in the All Patient (AP) Intent to Treat (ITT) Population

PFS is defined as the interval between the date of randomization and the earliest documented evidence of disease progression based on the independent radiologic review using modified RECIST Version 1.1-(mRECIST 1.1) Gastrointestinal stromal tumor (GIST) specific, or death due to any cause. Per mRECIST 1.1, progression was defined using mRECIST 1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
From date of randomization to earliest documented evidence of disease progression, or death due to any cause (up to 2.1 years)
Reported as:
Median · months
Progression Free Survival (PFS) in the All Patient (AP) Intent to Treat (ITT) Population
monthsRipretinibSunitinib
Progression Free Survival (PFS) in the All Patient (AP) Intent to Treat (ITT) Population8.0 (6.5 to 10.8)8.3 (6.3 to 11.0)
Statistical analysis
  • Ripretinib vs Sunitinib · Log Rank · p = 0.7153 (Two-sided P-value) · Hazard ratio (hr): 1.05 · 95% CI 0.82 to 1.33Strata: mutation status (KIT exon 9 vs. 11 vs. KIT/PDGFRA WT vs. other KIT {absence of exon 9 or 11}/PDGFRA) and intolerance to imatinib treatment
SecondaryObjective Response Rate (ORR) in the KIT Exon 11 Intent to Treat (ITT) Population Population

ORR was defined as the proportion of patients with confirmed complete response (CR) + confirmed partial response (PR) based on independent radiologic review using modified RECIST (mRECIST) criteria as best overall response. Per mRECIST 1.1 criteria, complete response is defined as disappearance of all target lesions; partial response is defined as \>=30% decrease in the sum of the longest diameter of target lesions.

Time frame:
From confirmed CR or PR to disease progression (up to 1.74 years)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) in the KIT Exon 11 Intent to Treat (ITT) Population Population
percentage of participantsRipretinibSunitinib
Objective Response Rate (ORR) in the KIT Exon 11 Intent to Treat (ITT) Population Population23.9 (17.6 to 31.2)14.6 (9.6 to 21.0)
Statistical analysis
  • Ripretinib vs Sunitinib · Cochran-Mantel-Haenszel · p = 0.0333Strata: intolerance to imatinib treatment
SecondaryObjective Response Rate (ORR) in the All Patient (AP) Intent to Treat (ITT) Population

ORR was defined as the proportion of patients with confirmed complete response (CR) + confirmed partial response (PR) based on independent radiologic review using modified RECIST (mRECIST) criteria as best overall response. Per mRECIST 1.1 criteria, complete response is defined as disappearance of all target lesions; partial response is defined as \>=30% decrease in the sum of the longest diameter of target lesions.

Time frame:
From confirmed CR or PR to disease progression (up to 1.74 years)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) in the All Patient (AP) Intent to Treat (ITT) Population
percentage of participantsRipretinibSunitinib
Objective Response Rate (ORR) in the All Patient (AP) Intent to Treat (ITT) Population21.7 (16.5 to 27.6)17.6 (12.9 to 23.2)
Statistical analysis
  • Ripretinib vs Sunitinib · Cochran-Mantel-Haenszel · p = 0.2681Strata: mutation status (KIT exon 9 vs. 11 vs. KIT/PDGFRA WT vs. other KIT {absence of exon 9 or 11}/PDGFRA) and intolerance to imatinib treatment
SecondaryOverall Survival (OS) in the KIT Exon 11 Intent to Treat (ITT) Population

OS was defined as the time from the date of randomization until death due to any cause.

Time frame:
From date of randomization until death due to any cause (up to 3.33 years)
Reported as:
Median · months
Overall Survival (OS) in the KIT Exon 11 Intent to Treat (ITT) Population
monthsRipretinibSunitinib
Overall Survival (OS) in the KIT Exon 11 Intent to Treat (ITT) Population34.0 (29.3 to NA)31.5 (29.4 to NA)
Statistical analysis
  • Ripretinib vs Sunitinib · Log Rank · p = 0.7733 · Hazard ratio (hr): 1.05 · 95% CI 0.75 to 1.48Strata: intolerance to imatinib treatment
SecondaryOverall Survival (OS) in the All Patient (AP) Intent to Treat (ITT) Population

OS was defined as the time from the date of randomization until death due to any cause.

Time frame:
From date of randomization until death due to any cause (up to 3.33 years)
Reported as:
Median · months
Overall Survival (OS) in the All Patient (AP) Intent to Treat (ITT) Population
monthsRipretinibSunitinib
Overall Survival (OS) in the All Patient (AP) Intent to Treat (ITT) Population35.5 (29.3 to NA)30.9 (28.9 to NA)
Statistical analysis
  • Ripretinib vs Sunitinib · Log Rank · p = 0.3928 · Hazard ratio (hr): 0.88 · 95% CI 0.66 to 1.18Strata: mutation status (KIT exon 9 vs. 11 vs. KIT/PDGFRA WT vs. other KIT {absence of exon 9 or 11}/PDGFRA) and intolerance to imatinib

Adverse events

Collected over Collection of Adverse events started from the signing of informed consent through safety follow-up (up to 3.22 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ripretinib90/223 (40.4%)64/223 (28.7%)221/223 (99.1%)
Sunitinib95/221 (43%)61/221 (27.6%)219/221 (99.1%)
Most frequent serious events
Showing 10 of 112
Most frequent serious events
EventRipretinibSunitinib
Abdominal painGastrointestinal disorders6/2236/221
General physical health deteriorationGeneral disorders5/2230/221
COVID-19Infections and infestations5/2232/221
AnaemiaBlood and lymphatic system disorders4/2232/221
Urinary tract infectionInfections and infestations2/2233/221
Atrial fibrillationCardiac disorders3/2230/221
Small intestinal obstructionGastrointestinal disorders2/2232/221
DiarrhoeaGastrointestinal disorders1/2232/221
Gastrointestinal perforationGastrointestinal disorders0/2232/221
PyrexiaGeneral disorders0/2232/221
Most frequent other events
Showing 10 of 61
Most frequent other events
EventRipretinibSunitinib
AlopeciaSkin and subcutaneous tissue disorders144/22318/221
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders61/223116/221
DiarrhoeaGastrointestinal disorders47/223107/221
HypertensionVascular disorders60/223106/221
FatigueGeneral disorders84/22391/221
StomatitisGastrointestinal disorders18/22381/221
MyalgiaMusculoskeletal and connective tissue disorders81/22325/221
ConstipationGastrointestinal disorders79/22348/221
Decreased appetiteMetabolism and nutrition disorders60/22354/221
Muscle spasmsMusculoskeletal and connective tissue disorders59/22315/221

Baseline characteristics

Age, Customized
Age, Customized(Participants)RipretinibSunitinibTotal
18-64 years145143288
65-74 years5666122
75 years and older251843
Sex: Female, Male
Sex: Female, Male(Participants)RipretinibSunitinibTotal
Female8785172
Male139142281
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RipretinibSunitinibTotal
Black or African American141428
American Indian or Alaska Native011
Asian312758
Native Hawaiian or Other Pacific Islander213
White148152300
Not Report303060
Other123
Eastern Cooperative Oncology Group (ECOG) Score at Screening
Eastern Cooperative Oncology Group (ECOG) Score at Screening(Participants)RipretinibSunitinibTotal
ECOG Score 0131128259
ECOG Score 19298190
ECOG Score 2314
Mutation Type per Electronic Data Capture (EDC)
Mutation Type per Electronic Data Capture (EDC)(Participants)RipretinibSunitinibTotal
KIT Exon 9312859
KIT Exon 11167169336
KIT/PDGFRA WT141630
Other KIT (absence of Exon 9 or 11)/PDGFRA141428
Intolerance to Imatinib per Electronic Data Capture (EDC)
Intolerance to Imatinib per Electronic Data Capture (EDC)(Participants)RipretinibSunitinibTotal
Yes151934
No211208419
Mutation Type per Interactive Response Technology (IRT)
Mutation Type per Interactive Response Technology (IRT)(Participants)RipretinibSunitinibTotal
KIT Exon 9312960
KIT Exon 11163164327
KIT/PDGFRA wild type (WT)151833
Other KIT (absence of Exon 9 or 11)/PDGFRA171633
Intolerance to Imatinib per Interactive Response Technology (IRT)
Intolerance to Imatinib per Interactive Response Technology (IRT)(Participants)RipretinibSunitinibTotal
Yes222345
No204204408
08

Study locations

121 sites

Showing the first 100 of 121 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Heinrich MC, Blay JY, Gelderblom H, George S, Schoffski P, von Mehren M, Zalcberg JR, Jones RL, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Boye K, Goldstein D, Sanchez C, Siontis BL, Cox P, Davis E, Sherman ML, Ruiz-Soto R, Bauer S. Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE. J Clin Oncol. 2025 Jul 10;43(20):2239-2244. doi: 10.1200/JCO-24-02818. Epub 2025 May 23. PubMed 40408605 ↗
  • Heinrich MC, Jones RL, George S, Gelderblom H, Schoffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Reichmann W, Sprott K, Achour H, Sherman ML, Ruiz-Soto R, Blay JY, Bauer S. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med. 2024 Feb;30(2):498-506. doi: 10.1038/s41591-023-02734-5. Epub 2024 Jan 5. PubMed 38182785 ↗
  • Gelderblom H, Jones RL, Blay JY, George S, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Harrow B, Becker C, Reichmann W, Sherman ML, Ruiz-Soto R, Heinrich MC, Bauer S; INTRIGUE investigators. Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study. Eur J Cancer. 2023 Oct;192:113245. doi: 10.1016/j.ejca.2023.113245. Epub 2023 Jul 20. PubMed 37598656 ↗
  • Bauer S, Jones RL, Blay JY, Gelderblom H, George S, Schoffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Su Y, Meade J, Wang T, Sherman ML, Ruiz-Soto R, Heinrich MC. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2022 Dec 1;40(34):3918-3928. doi: 10.1200/JCO.22.00294. Epub 2022 Aug 10. PubMed 35947817 ↗
  • Nemunaitis J, Bauer S, Blay JY, Choucair K, Gelderblom H, George S, Schoffski P, Mehren MV, Zalcberg J, Achour H, Ruiz-Soto R, Heinrich MC. Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. Future Oncol. 2020 Jan;16(1):4251-4264. doi: 10.2217/fon-2019-0633. Epub 2019 Nov 22. PubMed 31755321 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2019 to primary completion in Sep 2021, 30 months.

Results were first posted in Jan 2024, 2 years 4 months after primary completion.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2027, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2018
First posted
Sep 17, 2018
StartActual
Feb 8, 2019
Primary completionActual
Sep 1, 2021
CompletionEst.
Dec 2027was Dec 2026
Results first posted
Jan 2, 2024
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Dec 2026→Dec 2027
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Study completion Dec 2026→Dec 2027
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03673501
Responsible party
Sponsor
First posted
Sep 17, 2018
Start date
Feb 8, 2019
Primary completion
Sep 1, 2021
Completion
Dec 2027 (estimated)
Results posted
Jan 2, 2024
Last update
Oct 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ripretinib

Start the discussion